BC
CABA icon

Bridgefront Capital’s Cabaletta Bio CABA Stock Holding History

Bridgefront Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,229
Closed -$57.7K – 601
2024
Q3 		$57.7K Buy
12,229
+353
+3% +$2.04K 0.02% 500
2024
Q2 		$88.8K Buy
+11,876
New +$146K 0.04% 452

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's CABA Position: Q4 2024 in Review

Bridgefront Capital sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 12,229 shares — an estimated $57.7K sold.

Bridgefront Capital first reported a position in CABA in Q2 2024 and held it in 2 quarters. The position peaked at $88.8K in Q2 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • Bridgefront Capital reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • Bridgefront Capital sold 12,229 Cabaletta Bio shares in Q4 2024, an estimated $57.7K.
  • Bridgefront Capital first reported a position in Cabaletta Bio in Q2 2024 and held it in 2 quarters.
  • Bridgefront Capital's Cabaletta Bio position peaked at $88.8K in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on Bridgefront Capital's 13F filing for Q4 2024, filed 14 Feb 2025.